NEW YORK (
) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good.
Highlights from the ratings report include:
- The revenue growth came in higher than the industry average of 11.8%. Since the same quarter one year prior, revenues rose by 28.6%. Growth in the company's revenue appears to have helped boost the earnings per share.
- Powered by its strong earnings growth of 673.33% and other important driving factors, this stock has surged by 39.53% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, our hold rating indicates that we do not recommend additional investment in this stock despite its gains in the past year.
- VERENIUM CORP reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. However, we anticipate underperformance relative to this pattern in the coming year. During the past fiscal year, VERENIUM CORP turned its bottom line around by earning $0.41 versus -$1.14 in the prior year. For the next year, the market is expecting a contraction of 261.0% in earnings (-$0.66 versus $0.41).
- VRNM's debt-to-equity ratio of 0.86 is somewhat low overall, but it is high when compared to the industry average, implying that the management of the debt levels should be evaluated further. Regardless of the somewhat mixed results with the debt-to-equity ratio, the company's quick ratio of 1.33 is sturdy.
Verenium Corporation, a biotechnology company, develops, manufactures, and commercializes enzymes for industrial processes in North America, Europe, South America, and Asia. The company has a P/E ratio of 8.7, below the average chemicals industry P/E ratio of 8.9 and below the S&P 500 P/E ratio of 17.7. Verenium has a market cap of $46 million and is part of the
industry. Shares are up 68.3% year to date as of the close of trading on Monday.
You can view the full
or get investment ideas from our
-- Written by a member of TheStreet RatingsStaff